Clinical Nuclear Medicine · 2013 · 21 citations · 22 references
MedicineOncologyMetastasisOncologic ImagingOncologic Nuclear MedicineBone Metastasis ImagingCancer StagingLung MetastasisMalignant NeoplasmsTumor CharacterizationTumor ImagingBone Metastasis StagingDistant Metastasis DetectionDistant Metastasis StagingIntracranial MetastasesLiver Metastasis ImagingMetastatic Tumor DetectionOncologic Pet ImagingPretreatment Staging
OBJECTIVE: Diagnostic efficacy of (18)F-FLT PET was compared with that of (18)F-FDG PET regarding second primary cancers and distant metastases of head and neck squamous cell cancers (HNSCCs). METHODS: A total of 88 patients with HNSCCs were qualitatively examined with FLT PET and FDG PET for regions of focally increased metabolism. Final diagnoses of second primary cancer and distant metastasis were established on the basis of histological findings or clinical follow-up. RESULTS: FDG PET had 1 false-negative finding with lung metastasis, and FLT PET had 4 false-negative findings with 1 liver metastasis, 1 bone metastasis, and 2 lung metastases. There were no false-positive findings with FLT PET in contrast to 9 with FDG PET (1 in lung, 4 in mediastinum, 1 in rectum, and 3 in stomach). Overall accuracy of FDG PET and FLT PET for pretreatment metastasis staging was 92% and 98%, respectively. Five distant metastases in 3 patients occurred after the initiation of chemoradiotherapy. FLT PET missed 2 metastatic lesions (1 in liver and 1 in lung), whereas FDG PET could not discriminate intracranial metastasis because of FDG uptake in the brain. CONCLUSIONS: FLT PET does not appear to be recommendable to replace FDG PET for pretreatment metastasis staging in HNSCC cases because of its lower sensitivity and higher background activity in the liver and bone marrow. However, it might provide additional diagnostic specificity and biological information.
22
Gerald Antoch, Nina Saoudi, Hilmar Kuehl et al. · Journal of Clinical Oncology · 2004 · 435 citations
Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells.
Janet S. Rasey, John R. Grierson, Linda Wiens et al. · PubMed · 2002 · 407 citations
Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
Andreas K. Buck, G. Halter, Holger Schirrmeister et al. · PubMed · 2003 · 404 citations